Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (356)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06623474 | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma | recruiting | — | 900 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 |
| Oct 8, 2024 |
| clinicaltrials |
| NCT06624098 | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma | recruiting | N/A | 22 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | recruiting | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06593964 | TACE With Thermosensitive Nanogel Versus Embosphere for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601231 | To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.(ADRENALIN) | recruiting | — | 1,000 | Erasmus Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06581315 | Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma | recruiting | N/A | 204 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06561399 | Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) | recruiting | — | 28 | Fujian Provincial HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06559761 | Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research | recruiting | — | 500 | Chinese PLA General HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06550921 | Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma | recruiting | N/A | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06519578 | Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 1,115 | RenJi HospitalOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De ToniOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06478927 | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib | recruiting | N/A | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06470256 | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Zhiyong HuangOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06204835 | ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery | recruiting | Phase 1 | 90 | Institute of Automation, Chinese Academy of SciencesOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06418165 | Vienna Hypothermic Oxygenated Machine Perfusion Study(VIHOMPS) | recruiting | — | 500 | Medical University of ViennaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05866783 | Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma(GLITCA) | recruiting | — | 500 | University Hospital, GhentOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06397222 | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | recruiting | Phase 2 | 23 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06398028 | The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound. | recruiting | Phase 4 | 173 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | recruiting | Phase 3 | 196 | Wen TianfuOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | recruiting | Phase 2 | 111 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 57 | Fujian Medical UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05714124 | Liver Embolization Approaches for Tumor Management(LEATUM) | recruiting | — | 580 | IRCCS San RaffaeleOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363006 | Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer | recruiting | Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06241326 | Immunotherapy for Hepatocellular Carcinoma(IFHC) | recruiting | — | 11,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06326502 | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Etnova Therapeutics Corp.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06261125 | Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)(HSBRT2401) | recruiting | Phase 2 | 60 | Mian XIOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05970666 | Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 71 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06265350 | Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | recruiting | N/A | 80 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05794048 | METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors(PROMETHEP) | recruiting | N/A | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06236568 | Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation | recruiting | N/A | 40 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06244225 | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06219096 | Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection | recruiting | N/A | 100 | West China HospitalOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06205472 | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06190665 | DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | recruiting | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 9, 2024source: clinicaltrials